BridgeBio Oncology Therapeutics, Inc. (BBOT) Form S-3 — Sep 1, 2026
BridgeBio Oncology Therapeutics filed a new Form S-3 shelf registration statement on September 1, 2026 covering up to $500,000,000 of common stock, preferred stock, debt securities, warrants, and units, to be offered from time to time. The filing includes a $200,000,000 at-the-market equity program under a Sales Agreement dated September 1, 2026 with Leerink Partners and Cantor Fitzgerald & Co., who earn up to a 3.0% commission on gross proceeds. At the assumed price of $8.80 (the August 31, 2026 close), full utilization would issue roughly 22.7 million new shares, lifting shares outstanding from 80.1 million to about 102.8 million — an approximately 28% increase.
Key figures
- Gross Proceeds
- Up to $500,000,000 total securities under shelf; $200,000,000 ATM component
- Offering Price
- 8.8
- Shares Outstanding
- 80115002
- Board Size
- 8
- Assumed Price Basis
- $8.80 was the last reported Nasdaq sale price on August 31, 2026
- Options Outstanding
- 12600655
- Net Tangible Book Value
- $323.1 million ($4.03/share) as of June 30, 2026
- Authorized Common Shares
- 500000000
- Sales Agent Commission Max
- Up to 3.0% of gross proceeds
- Authorized Preferred Shares
- 10000000
- Pro Forma Shares Outstanding
- 102842274
- Atm Max Shares At Assumed Price
- 22727272
- Potential Share Count Increase
- ~28.4% if ATM fully utilized at assumed $8.80
- Pro Forma Net Tangible Book Value
- $516.6 million ($5.02/share) after full $200.0 million ATM at $8.80
- Dilution To New Investors Per Share
- $3.78 at assumed $8.80
- Options Weighted Avg Exercise Price
- 8.42
Price after filing
Close on the filing date to close N calendar days later (from $8.82). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.